Information Provided By:
Fly News Breaks for November 25, 2019
Nov 25, 2019 | 08:33 EDT
Baird analyst Madhu Kumar raised his price target on Dicerna (DRNA) to $50 from $35 following the buyout offer of The Medicines Company (MDCO) by Novartis (NVS). The analyst said the offer caused him to reassess its cardiovascular disease platform and its multiple value-added partnerships with other major drug makers. Kumar reiterated his Outperform rating on Dicerna shares.
News For DRNA From the Last 2 Days
There are no results for your query DRNA